Bi Xiaolin, Liu Xuan, Di Liuqing, Zu Qiang
College of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing 210023, China.
Molecules. 2016 Apr 8;21(4):456. doi: 10.3390/molecules21040456.
The active ingredients of salvia (dried root of Salvia miltiorrhiza) include both lipophilic (e.g., tanshinone IIA, tanshinone I, cryptotanshinone and dihydrotanshinone I) and hydrophilic (e.g., danshensu and salvianolic acid B) constituents. The low oral bioavailability of these constituents may limit their efficacy. A solid self-microemulsifying drug delivery system (S-SMEDDS) was developed to load the various active constituents of salvia into a single drug delivery system and improve their oral bioavailability. A prototype SMEDDS was designed using solubility studies and phase diagram construction, and characterized by self-emulsification performance, stability, morphology, droplet size, polydispersity index and zeta potential. Furthermore, the S-SMEDDS was prepared by dispersing liquid SMEDDS containing liposoluble extract into a solution containing aqueous extract and hydrophilic polymer, and then freeze-drying. In vitro release of tanshinone IIA, salvianolic acid B, cryptotanshinone and danshensu from the S-SMEDDS was examined, showing approximately 60%-80% of each active component was released from the S-SMEDDS in vitro within 20 min. In vivo bioavailability of these four constituents indicated that the S-SMEDDS showed superior in vivo oral absorption to a drug suspension after oral administration in rats. It can be concluded that the novel S-SMEDDS developed in this study increased the dissolution rate and improved the oral bioavailability of both lipophilic and hydrophilic constituents of salvia. Thus, the S-SMEDDS can be regarded as a promising new method by which to deliver salvia extract, and potentially other multicomponent drugs, by the oral route.
丹参(丹参干燥根)的活性成分包括亲脂性成分(如丹参酮IIA、丹参酮I、隐丹参酮和二氢丹参酮I)和亲水性成分(如丹酚酸和丹酚酸B)。这些成分口服生物利用度低可能会限制其疗效。开发了一种固体自微乳化药物递送系统(S-SMEDDS),将丹参的各种活性成分载入单一药物递送系统中,提高其口服生物利用度。利用溶解度研究和相图构建设计了一种原型SMEDDS,并通过自乳化性能、稳定性、形态、液滴大小、多分散指数和ζ电位进行表征。此外,通过将含有脂溶性提取物的液体SMEDDS分散到含有水提取物和亲水性聚合物的溶液中,然后冷冻干燥来制备S-SMEDDS。考察了S-SMEDDS中丹参酮IIA、丹酚酸B、隐丹参酮和丹酚酸的体外释放情况,结果表明,在20分钟内,每种活性成分约60%-80%从S-SMEDDS中释放出来。这四种成分的体内生物利用度表明,在大鼠口服给药后,S-SMEDDS的体内口服吸收优于药物混悬液。可以得出结论,本研究开发的新型S-SMEDDS提高了丹参亲脂性和亲水性成分的溶解速率,改善了其口服生物利用度。因此,S-SMEDDS可被视为一种有前景的新方法,用于通过口服途径递送丹参提取物以及潜在的其他多组分药物。